Related posts

Most Anticipated Earnings: NTR-T, ONEX-T and more Canadian Companies Reporting Earnings this Week (Feb 17-21)Weekly 52-Week Low (or 52-Week High): BB-T, AEM-T, DOO-T, TSU-T and More 52-Week Highs and Lows (Jan 29-Feb 04)Weekly 52-Week Low (or 52-Week High): BB-T, AEM-T, DOO-T, TSU-T and More 52-Week Highs and Lows (Jan 29-Feb 04)
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Kneat.com Inc (KSI-X) is making significant strides in the biopharma sector with its validation software solutions. Experts note that the company has demonstrated a robust performance chart, indicative of strong growth potential. Following a period of losses attributed to R&D investments, Kneat.com is now on a path to profitability, which is considered a positive turnaround. Analysts highlight that when Kneat.com secures a client, the integration and rollout process may take time, but they are confident that this growth trajectory is sustainable. There is a general expectation of rapidly expanding profit margins in the coming years, suggesting that the company is well-positioned for future success.

Consensus
Positive
Valuation
Undervalued
BUY

They bring validation software to biopharma, and they do it well. The chart is strong. He's been adding shares. Before, they were losing as they invested in R&D, but now they're becoming profitable. He expects margins to expand quickly in coming years. When they win a client, it takes time to roll out that client. Growth is safe.

Technology
PAST TOP PICK
(A Top Pick Aug 22/22, Down 17%)

Software company that is based in Ireland. 
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers. 
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.


Technology
TOP PICK
Has developed propriety software product to aid with compliance in the life science industry. Business has very high barriers to entry. Customer list includes 8 of the top 10 pharma companies. 60 contracted customers going forward.
Technology
BUY
A company that has a software to bring efficiency to the pharmaceutical industry. It helps with work flows. Their strategy is land and expand. Results were better than expected. The sales cycle is long. There is significant upside as they convert to sales and visible recurring revenue. Higher profitability is on the horizon.
Technology
Showing 1 to 4 of 4 entries
  • «
  • 1
  • »

Kneat.com Inc(KSI-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Kneat.com Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Kneat.com Inc(KSI-X) Frequently Asked Questions

What is Kneat.com Inc stock symbol?

Kneat.com Inc is a Canadian stock, trading under the symbol KSI-X on the TSX Venture Exchange (KSI-CV). It is usually referred to as TSXV:KSI or KSI-X

Is Kneat.com Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about KSI-X. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Kneat.com Inc.

Is Kneat.com Inc a good investment or a top pick?

Kneat.com Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Kneat.com Inc.

Why is Kneat.com Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Kneat.com Inc worth watching?

1 stock analyst on Stockchase covered Kneat.com Inc In the last year. It is a trending stock that is worth watching.

What is Kneat.com Inc stock price?

On 2021-11-12, Kneat.com Inc (KSI-X) stock closed at a price of $4.25.